| Autor: |
Amengual, J. E., Shyr, Y., Durecki, D., Beumer, J. H., Mansukhani, M. M., Williams, M., Kelleher, N., Cherng, H., Pro, B., Schwartz, G. K., LoRusso, P., Piekarz, R. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p833-834, 2p |
| Abstrakt: |
The goal of the ETCTN P10500 study is determine if dual epigenetic targeting with tazemetostat and belinostat is safe for lymphoma patients, to determine the phase 2 dose, and to explore potential biomarkers for response. The expansion cohort will be stratified by EZH2 mutation status, with a goal of enrolling 6 mutated and 6 wild-type EZH2 lymphoma patients. New findings have identified several DLBCL clusters, including the EZB-GC-DLBCL subtype that is enriched in mutations of CREBBP, EP300, and EZH2 (Wright 2020; Schmitz 2018; Chapuy 2018). [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text